Lead sponsor
HealthPartners Institute
5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
5
Trials led
0
Active
148
Total enrollment
5
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
5
Trials by status
Completed
5
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin GlargineHbA1c ≥7%not applicableCompleted60
Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With ExenatideHbA1c 7.1-11%not applicableCompleted18
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic ControlBMI 25-45not applicableCompleted16
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly ExenatideBMI 25-45not applicableCompleted8